Treatment with selective inhibitors targeting HDAC6 significantly improves Alzheimer's disease phenotypes, highlighting its potential as a promising therapeutic target warranting further investigation. This evidence concerns the gene HDAC6 and early-onset autosomal dominant Alzheimer disease.